SYnAbs, a Belgian company, is involved in the manufacture of Innovative mAbs against poor immunogenic compounds and complex antigens.
SYnAbs’ vision is to fill the gap for innovative monoclonal antibodies against poor immunogenic compounds and complex antigens. Targeting transmembrane proteins, steroids, small molecules, toxins, lipids and polysaccharides, SYnAbs has developed a strong expertise in immunology to break immunotolerance in rat species to generate unique monoclonal antibodies of extreme specificity and higher affinity.
With their unique expertise, SYnAbs team has generated unique monoclonal antibodies, bringing added value in the fields of hormones, toxins, auto-immune diseases and oncology.
The unique multi-species immunisation platform enables SYnAbs to increase the probability getting the unique monoclonal you’re looking for.